Glypican-1 (GPC1) is highly expressed in solid tumors, especially squamous cell carcinomas (SCCs), and is thought to be associated with disease progression. We explored the use of a GPC1-targeted antibody-drug conjugate (ADC) as a novel treatment for uterine cervical cancer. On immunohistochemical staining, high expression levels of GPC1 were detected in about 50% of uterine cervical cancer tissues and also in a tumor that had relapsed after chemoradiotherapy. Novel anti-GPC1 monoclonal antibodies were developed, and clone 01a033 was selected as the best antibody for targeted delivery of the cytotoxic agent monomethyl auristatin F (MMAF) into GPC1-positive cells. The anti-GPC1 antibody was conjugated with MMAF. On flow cytometry, HeLa and ME180 cervical cancer cells highly expressed GPC1, however, RMG-I ovarian clear cell cancer cell line showed weak expression. The GPC1-ADC was rapidly internalized into GPC1-expressing cells in vitro and was potently cytotoxic to cancer cells highly expressing GPC1. There were no inhibitory effects on cancer cells with low expression of GPC1. In a murine xenograft model, GPC1-ADC also had significant and potent tumor growth inhibition. GPC1-ADC-mediated G2/M phase cell cycle arrest was detected, indicating that the dominant antitumor effect in vivo was MMAF-mediated. The toxicity of GPC-ADC was tolerable within the therapeutic dose range in mice. Our data showed that GPC1-ADC has potential as a promising therapy for uterine cervical cancer.
antibody that selectively binds to an internalizing tumorassociated antigen. 3, 4 This strategy allows specific delivery of the cytotoxic agent to the tumor site while minimizing the exposure of normal tissues to the drug. The prospects for development of ADCs as an effective, well tolerated, anticancer therapy have changed dramatically since the approval of brentuximab vedotin in 2011 for CD30-positive lymphomas 5, 6 and ado-trastuzumab emtansine in 2013 for HER2-positive breast cancer. [7] [8] [9] Currently, >50 different ADCs are in clinical development, most consisting of IgG1 antibodies conjugated to a potent microtubule inhibitor, either maytansine or auristatin. While these drugs are too toxic to be administered systemically, 10, 11 they produce cytotoxicity at lower concentrations than do current standard chemotherapeutic agents. Therefore, by conjugating these potent cytotoxins with tumor-specific antibodies, the cytotoxic effects can be specifically targeted to antigen-expressing tumor cells. While ADCs have been shown to be potent targeted treatment for various cancers, only a limited number of studies were reported in cervical cancer. [12] [13] [14] Recently, our group identified glypican-1 (GPC1) as a cancer antigen in esophageal squamous cell carcinoma (ESCC) by a quantitative proteomic approach focused on cell surface membrane proteins. 15 We confirmed the limited or relatively low expression of GPC1 in normal tissues compared with ESCC tissues. 16 GPC1 is a heparan sulfate proteoglycan that binds to the external surface of the plasma membrane by a glycosyl-phosphatidylinositol anchor. 17, 18 We also demonstrated that targeting GPC1 with an anti-GPC1 monoclonal antibody (mAb) had a strong antitumor effect via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in both a dependent and independent manner. Importantly, anti-GPC1 mAb also induced potent tumor growth inhibition in xenograft models using patient-derived GPC1-positive ESCC tumors, 16 suggesting that GPC1 would be a promising therapeutic target in ESCC. Elevated expression of GPC1 has been reported in breast cancer, glioblastoma and pancreatic cancer. [19] [20] [21] [22] [23] Expression levels of GPC1 have not, however, been evaluated in uterine cervical cancer. This study aimed to assess the expression of GPC1 in uterine cervical cancer and investigate the possibility of it being a new therapeutic target, with GPC1-ADC as a novel drug delivery technology. 
Material and Methods

Patients
Immunohistochemistry
Surgically resected tumor tissues were obtained from patients with uterine cervical cancer at Osaka University Hospital. All sections were prepared from formalin-fixed, paraffin-embedded 4-lm tissue sections. Evaluation of GPC1 expression in tumor tissues was performed using a rabbit polyclonal anti-GPC1 antibody (Atlas Antibodies AB, Stockholm, Sweden, 1:400) and visualized using Envision ChemMate (Dako, Glostrup, Denmark) according to the manufacturer's protocol. Three independent gynecologic oncologists (SM, KY, YU) who were blinded to the clinical data analyzed the stained sections, which were also photographed using phase contrast light microscopy (DM2500 with Leica Application Sweat version 3.80; Leica Microsystems GmbH, Wetzlar, Germany). Immunostaining was scored according to the intensity of the staining: 0, no staining; 1, weak staining (i.e., lower than in the basal layer); 2, strong staining (the same or stronger as in the basal layer). The density of staining was as follows: 0, indicated 0-9% positivity; 1, indicated 10-40%; 2, indicated 41-70%; and 3, indicated 71-100% positivity. The final immunohistochemistry (IHC) score was determined by multiplying the intensity score by the density score, resulting in a maximum possible score of 6. These data were referred to as the GPC1 score. We evaluated GPC1 expression by calculating scores for both histologic types of cervical cancer, SCC and adenocarcinoma (AC).
Cell lines and culture
Two human cervical cancer cell lines [HeLa (AC) and ME180 (SCC)] and a human ovarian clear cell carcinoma cell What's new? Antibody-drug conjugates (ADC) are potent targeted treatments for various cancers, but their potential for cervical cancer remains little explored. After showing that Glypican-1 (GPC1) is highly expressed in cervical cancer, the authors developed a novel anti-GPC1 monoclonal antibody with cell internalization activity to produce an ADC linked to the cytotoxic agent monomethyl auristatin F. The ADC potently inhibited the growth of GPC1-positive cervical cancer cells in vitro and in vivo. Because GPC1 expression levels in normal tissues are lower than in cancer cells, targeting GPC1 with an ADC could be an attractive therapeutic approach for cervical and other GPC1-expressing tumors.
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line (RMG-1) were obtained from the Japanese Collection of Research Bioresources (Osaka, Japan). HeLa and RMG-1 cells were maintained in RPMI 1640 medium. ME180 cells were maintained in DMEM. All media were supplemented with 10% fetal bovine serum (Serum Source International, Charlotte, NC) with 100 U/ml penicillin and 100 lg/ml streptomycin (Nacalai Tesque, Kyoto, Japan). Cultures were maintained at 378C in a humidified 5% CO 2 atmosphere. The identity of each cell line was confirmed by DNA fingerprinting using short tandem repeat profiling, as previously described. 24 
Antibody generation
To generate mAbs against human GPC1, 4-6-week-old mice with MRL or C3H backgrounds, were immunized with recombinant human GPC1 protein (R&D Systems, Minneapolis, MN). Detailed methods are described in the online Supporting Information Methods.
Quantitative flow cytometric analysis
Cell surface GPC1 expression levels were quantified with QIFIKIT flow cytometric indirect immunofluorescence assay (Dako, Hamburg, Germany) using anti-GPC1 mAb (clone 01a033) as the primary antibody. 
Preparation of antibody-drug conjugate
The anti-GPC1 mAb (clone 01a033) and isotype control antibody (mouse IgG2a, clone MOPC-173, BioLegend, San Diego, CA) were used to manufacture the ADC. The anti-GPC1 mAb was partially reduced with tris-(2-carboxyethylphosphine) hydrochloride, followed by reaction with maleimidolcaproyl-valine-citrulline-paminobenzyloxycarbonyl-MMAF 25 to yield the GPC1-ADC and control-ADC. MMAF belongs to the dolastatin 10 family of highly potent antimitotic agents that inhibit tubulin polymerization; it is often used as the drug in the construction of an ADC. To remove residual unreactive toxins, the conjugated ADCs were desalted on Sephadex G50 columns, the buffer was exchanged for PBS, and the resulting ADC-containing solution was filtered. The drug distribution was analyzed by hydrophobic interaction chromatography.
Cytotoxicity assay
Cytotoxicity assays performed in the presence of anti-GPC1 mAb, mouse IgG2a isotype control antibody, GPC1-ADC, or control-ADC were assessed using cells plated at 1,000 to 2,000 per well in normal growth medium in flat bottom 96-well white polystyrene plates (Thermo Scientific). After 24 hrs, tumor cells were incubated with serial dilutions of anti-GPC1 mAb, GPC1-ADC, control-ADC, or mouse IgG2a isotype control antibody in hexaplicate wells for 144 hrs at 378C in a humidified 5% CO 2 atmosphere. Cell viability was determined with the CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega, WI), and luminescence values were measured using a microplate reader (SpectraMax Gemini EM). Curves were fitted according to nonlinear regression analysis of the data using GraphPad Prism v6.0 software. Results are reported as IC 50 , the concentration of compound needed to yield a 50% reduction in viability compared with vehicle-treated cells (control 5 100%) as described previously. 15 
Internalization studies
Cells were washed and collected as previously described. 24 Cells (1 3 10 6 cells/tube) were incubated for 1 hrs at 48C and further incubated with GPC1-ADC (clone 01a033) for 30 min at 48C. Cells were split into 1 3 10 5 cells/tube and incubated at 48C or 378C for internalization as indicated hours. Cells were washed, and the remaining surface GPC1 expression was reacted with biotin-labeled anti-GPC1 mAb (clone 02b006) for 30 min at 48C. The total bound anti-GPC1 mAb (clone 02b006) was set without incubation at 48C or 378C for internalization of GPC1-ADC (clone 01a033). The cells were then washed and incubated with streptavidin-PE (2.5 lg/ml) (BD Pharmingen, San Diego, CA). Fluorescence intensities were determined by flow cytometry (FACS Canto II cytometer). Internalization was quantified by calculating the percentage of internalization with the following formula: mean fluorescence intensity of cell surface GPC1 after induction of internalization as detected by anti-GPC1 mAb (clone 02b006) divided by the total bound anti-GPC1 mAb (clone 02b006) multiplied by 100 and subtracted from 100.
Fluorescence microscopy
HeLa and ME180 cells were plated on a coverglass (Micro coverglass, 18 3 18 mm, 0.12-to 0.17-mm thick; Matsunami Glass Ind., Osaka, Japan) at a density of 7.5 3 10 4 cells in 12-well plates in a growth medium and maintained at 378C in a humidified 5% CO 2 atmosphere. After 24 hrs, the medium was removed, ice-cold medium was added, and the cells were incubated at 48C for 1 hrs. ADCs were then added to the cells at 10 lg/ml and the cells incubated for 15 min at 48C. After incubation, ADCs were removed, cells were washed with the medium, 1.0 ml of warmed medium (378C) was added to the well, and the cells were incubated for 0 or 4 hrs at 378C. Cells were fixed and permeabilized using icecold methanol for 15 min at 2308C. After washing with PBS(-), blocking was performed using PBS(-) containing 1% BSA and 0.3% Triton X-100 for 1 hrs at room temperature. ADC was detected with donkey-anti-mouse IgG Alexa 488 (A21202; Life Technologies). LAMP1, a lysosomal marker, was detected with anti-CD107a mAb (#9091; Cell Signaling Technologies) followed by donkey-anti-rabbit IgG Alexa 647 (A31573; Life Technologies). Cells were mounted in Vectashield with DAPI (Vector Laboratories, Burlingame, CA). Images were acquired with a confocal microscope (LMS710, Zeiss, Oberkochen, Germany).
In vivo efficacy study
Healthy, female, 6 weeks old CB17/severe combined immunodeficient (SCID) mice were obtained from Charles River Japan (Yokohama, Japan) and maintained in a specific pathogen-free facility. For xenograft experiments, SCID mice were subcutaneously inoculated in the flank with 2.0 3 10 , the mice were randomly divided into five groups (6 or 7 mice/group). PBS, control-ADC (10 mg/kg), or varying doses of GPC1-ADC (1 mg/kg, 3 mg/kg, 10 mg/kg) were intravenously administered in 200 ll of PBS every fourth day for a total of 4 times. Tumor sizes were measured every 4 days using vernier calipers, and body weight was measured at the same time throughout the study. Tumor volumes were determined by measuring the length (L) and width (W) and calculating the volume as (W 2 3 L)/2. Tumors were resected 24 days (HeLa cells) or 32 days (ME180 cells) after the first treatment. All animal experiments were conducted according to the institutional ethical guidelines for animal experimentation of the National Institutes of Biomedical Innovation, Health and Nutrition.
To investigate pharmacologic action of GPC1-ADC at the cellular level, animals bearing ME180 tumor xenografts were injected with PBS, control-ADC (10 mg/kg), or GPC1-ADC (10 mg/kg), and the tumors were harvested 24 hrs later. Tumor sections were prepared from formalin-fixed, paraffinembedded 4-lm tissue sections. IHC analysis was performed with an antibody against a mitotic marker, anti-phospho histone H3 (Ser10) (#9701, Cell Signaling Technologies, 1:400). 26 In vivo toxicology studies Four male and female C57B/6J mice at 8 weeks were injected intraperitoneally with PBS, GPC1-ADC (3, 15, 50 mg/kg), or control-ADC (50 mg/kg). One week after administration, complete blood counts and serum chemistry were analyzed and dissected organs were stained with hematoxylin-eosin and evaluated by a pathologist.
Statistical analysis
Data are shown as mean 6 SD for in vitro experiments and mean 6 SEM for in vivo experiments. For comparisons among three or more groups, the values were analyzed by one-way ANOVA, followed by Dunnett's post hoc test. Mann-Whitney U test was used for significant differences between two groups. Differences were considered significant at p < 0.05.
Results
GPC1 is highly expressed in uterine cervical cancer specimens
To investigate GPC1 expression in uterine cervical cancer, we performed IHC with 68 specimens of SCC and 42 specimens of uterine cervical AC. We divided them into 3 groups based on the GPC1 score (Fig. 1a) . Among SCCs, 38 cases (56%) scored >4 points ("High" group), 24 cases (35%) scored 1 to 3 points ("Low" group), and 6 cases (9%) scored 0 points ("Negative" group). Among ACs, 21 cases (50%) were in the High group, 14 cases (33%) in the Low group, and 7 (17%) in the Negative group. The distribution of GPC1 expression is shown in Figure 1b . Interestingly, expression of GPC1 was also detected in tissue from a relapsed SCC of the uterine cervix after chemoradiation therapy (Fig. 1c) .
GPC1 is highly expressed in cervical cancer cell lines
To confirm the altered expression of GPC1 in uterine cervical cancer cell lines, a panel of murine anti-human GPC1 mAbs was generated by immunizing mice with recombinant human GPC1, and 18 clones of anti-GPC1 mAbs were established. The GPC1-binding activities of the mAbs were confirmed by flow cytometry using a GPC1-positive cell line and surface plasmon resonance analysis (Supporting Information Fig. S1 , Supporting Information Table 1 ). Among 18 clones, clone 01a033 was the best binding affinity to cell surface GPC1 by FACS analysis (Supporting Information Fig. S1 ). In addition, anti-GPC1 mAb clone 01a033 specifically reacted with recombinant human GPC1, because clone 01a033 did not react with other GPC family proteins (Supporting
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Information Fig. S2 ). Subsequently, using clone 01a033, flow cytometry was performed against two human uterine cervical cancer cell lines (HeLa and ME180) and a human ovarian clear cell cancer cell line (RMG-I). HeLa and ME180 cell lines had high expression levels of GPC1, while the expression of GPC1 was low in RMG-I cells. Thus, we used RMG-I cells as a negative control (Fig. 1d) . Quantitative measurement of GPC1 expression on the cell membrane by indirect immunofluorescence assay showed it to be high for both cervical cancer cell lines (HeLa; 53,884 sites/cell, ME180; 78,437 sites/cell), whereas the negative control RMG-I had low values (5,817 sites/cell; Table 2 ). These results support the notion that GPC1 was highly expressed in the cervical cancer.
Selection of a GPC1-binding monoclonal antibody (mAb) for an ADC and production of GPC1-ADC
Since GPC1 is overexpressed in various malignant solid cancers including uterine cervical cancer, compared with low expression in normal tissues, 16 we considered GPC1 to be an attractive target for development of ADC. To identify the optimal mAb for a GPC1-targeting ADC, mAbs were screened based on their ability to deliver an auristatin payload into GPC1-expressing cells in vitro using an indirect cytotoxicity assay exposing cells to anti-GPC1 mAb and MMAF-conjugated secondary antibody. Among 18 mAbs, clone 01a033 most efficiently delivered the MMAFconjugated secondary antibody into GPC1-positive cells (Supporting Information Table 2 ). We therefore selected clone 01a033 for the antibody component of the GPC1-ADC, and anti-GPC1 mAb 01a033 or an isotype control mouse IgG2a were directly conjugated with MMAF (Fig. 2a) . The drug-toantibody ratio was 4.1 for GPC1-ADC and 3. 
Internalization of GPC1-ADC was confirmed in HeLa and ME 180 cells
The binding capacity and percentage of internalization of anti-GPC1 mAb and GPC1-ADC were determined using flow-cytometry in HeLa and ME180. GPC1 remaining on the cell surface was measured by flow cytometry after each exposure to GPC1-ADC using biotin-labeled anti-GPC1 mAb (clone 02b006), which recognizes an epitope independent of that bound by clone 01a033 (Supporting Information Fig.  S3 ). The internalization of GPC1-ADC occurred rapidly in both cell lines (Fig. 2c) .
To confirm the translocation of GPC1-ADC to lysosomes, immunofluorescence analysis was performed, which had already been used to show GPC1-ADC binding to the cell membranes when preincubated at 48C before the internalization assay. When GPC1-ADC exposed cells were incubated at 378C for 4 hrs (Fig. 2d) , GPC1-ADC membrane staining was decreased and GPC1-ADC was found instead in the lysosomes, as evidenced by the overlap of staining for GPC1-ADC and the lysosomal marker LAMP-1 (Fig. 2d) . These results suggest that GPC1-ADC is first bound to the membrane of GPC1-expressing cells and is then internalized and translocated to the lysosomal compartment.
GPC1-ADC successfully inhibited proliferation of HeLa and ME 180 cells
To demonstrate that binding and internalization leads to effective and selective killing of GPC1-expressing human uterine cervical cancer cell lines, a cell growth assay using ADCs was performed using GPC1-positive HeLa and ME180 cells, with RMG-1 cells as a negative control. While unconjugated anti-GPC1 mAb had no effect on the viability of any of the cell lines, GPC1-ADC caused a dose-dependent decrease in cell viability in both HeLa and ME180 cells in vitro (Figs. 3a and 3b) . The IC 50 value of GPC1-ADC was 0.042 nM for HeLa and 0.093 nM for ME180 cells (Table 2) . However, GPC1-ADC did not significantly inhibit proliferation of RMG-1 cells (Figs. 3b) . The IC 50 of GPC1-ADC for RMG-1 was not calculated, since the cell inhibitory rate at 16 nM did not reach 50% (Fig. 3b) . Unconjugated anti-GPC1 mAb showed no cytotoxicity at concentrations up to 666.6 lM (data not shown). Since MMAF has poor cell membrane permeability, the sensitivity of cells to unconjugated MMAF was not high, as shown by IC 50 values of MMAF between 29.7 and 136.3 nM against each of the cell lines (Table 2 ). These data suggest that GPC1-ADC is internalized into the lysosome, presumably then releasing the MMAF to exert its toxic effects. The cytoxicity of the GPC1-ADC against GPC1-positive cells was also shown to be concentration dependent.
GPC1-ADC showed potent tumor growth inhibition in HeLa and ME180 xenografts
We evaluated the therapeutic effects of GPC1-ADC on uterine cervical cancer in vivo by establishing a xenograft model, implanting HeLa or ME180 cells subcutaneously in CB17/ SCID mice. Expression of GPC1 in these tumor tissues from xenografted mice was confirmed to be high and homogenous pattern (Figs. 4a and 4b) . When the mean tumor size of each cancer type reached approximately 130 mm 3 , PBS, control-ADC or GPC1-ADC was intravenously injected every four 
Cancer Therapy and Prevention
days for a total of 4 times. The growth of ME180 tumors in the group treated with control-ADC was similar to that in the PBS group (Fig. 4a) . In the two groups treated with 1 mg/kg or 3 mg/kg of GPC1-ADC, tumor growth was significantly suppressed compared with that in the control-ADC group after Day 8 and Day 12, respectively (p < 0.05; Fig.   4a ). Importantly, after Day 8, 10 mg/kg of GPC1-ADC significantly suppressed tumor growth even further than did the lower doses as compared with control-ADC (p < 0.001; Fig.  4a ). The growth of HeLa tumors was significantly less than in control-treated mice for the groups treated with 3 mg/kg (p < 0.01; after Day 20) and 10 mg/kg (p < 0.01; after Day 16) of GPC1-ADC (Fig. 4b ). Significant weight loss was not seen in any of the treatment groups (Figs.4a and 4b ). There was no significant difference in tumor volume between the group using 10 mg/kg of unconjugated anti-GPC1 mAb and the control IgG group in either the ME180 or HeLa xenograft model (Supporting Information Fig. S4 ).
To further analyze the pharmacologic action of GPC1-ADC in vivo using a mitotic marker antibody, IHC staining of ME180 xenograft tumors with phosphorylated histone H3 (Ser10) was performed. As expected, a marked increase in the percentage of tumor cells in mitosis was detected following treatment with GPC1-ADC but not with the control-ADC (Fig. 4c) . These results suggest that the tubulin polymerizing inhibitor MMAF was effectively delivered into the GPC1-expressing tumor cells by the anti-GPC1 mAb, causing mitotic arrest.
Adverse side effects did not occur in GPC1-ADC-treated mice
Since anti-GPC1 mAb crossreacts with mouse GPC1 (Supporting Information Fig. S5 ), a preliminary safety test of GPC1-ADC was conducted using male and female C57B/6 J mice. Administration of GPC1-ADC (3, 15, 50 mg/kg) did not result in significant weight loss compared with the group treated with control-ADC (50 mg/kg) (Supporting Information Fig. S6 ). Blood counts indicated no severe adverse effects on hematopoietic cells (Supporting Information Fig. S7 ). Alanine transaminase was elevated in both the control-ADC and GPC1-ADC groups when treated with doses of 50 mg/kg, but it was not high when the actual therapeutic dose of 15 mg/kg was administered (Supporting Information Fig. S8 ). There were no abnormal results specific to GPC1-ADC. Similarly, histopathologic examination revealed marked number of inflammatory cell infiltrates in the liver of both groups when treated with 50 mg/kg but only small number of inflammatory cell infiltrate in the GPC1-ADC group treated with 15 mg/kg (Supporting Information Fig. S9 ). The 50 mg/ kg dose was associated with increased numbers of macrophages and disorder of the follicular structure in the spleen in both the control-ADC group and the GPC1-ADC group. The same findings were observed in male and female mice (Supporting Information Fig. S9 ). These findings were not fatal, and we therefore considered that GPC1-ADC administration at the therapeutic dose was generally well tolerated.
Discussion
In this study, we demonstrated that GPC1 was highly expressed on the cell surface of a subset of cervical cancer tissues and cell lines. We also showed a high rate of GPC1 expression in cervical cancer specimens. We developed a unique GPC1-ADC and characterized its antitumor activity and safety. Interestingly, the ADC targeting GPC1 showed potent efficacy both in vitro and in vivo with limited toxicity. Because GPC1 expression levels in normal tissues are not as high as those in cancer cells, 16 targeting GPC1 with an ADC would be an attractive candidate for cancer therapy of GPC1-expressing tumors. Current therapies for cervical cancer, including surgery, radiation therapy, chemotherapy, and concurrent chemoradiation result in cure of 80% to 90% of stage I and early stage II cervical cancers. In contrast, the prognosis of patients in advanced stages or of residual or of recurrent cervical cancer is still very poor. Recently, paclitaxel-cisplatin therapy combined with bevacizumab has been used to treat recurrent or advanced cervical cancer, resulting in increased overall survival (17.0 months) compared with the same agents without bevacizumab (13.3 months), but the response rate was still below 50%, and severe complications such as gastrointestinal fistulas were observed in 3% of patients. 27, 28 Therefore, development of novel therapies is urgently required.
We found that the anti-GPC1 mAb was rapidly internalized into cells after binding to GPC1 on cancer cells, suggesting that GPC1 was a suitable target for constructing an ADC and that the anti-GPC1 mAb clone 01a033 was the most suitable clone, as it had high internalizing activity. We selected MMAF as the drug to conjugate with anti-GPC1 mAbs to produce the ADC. MMAF is an anti-tubulin agent that inhibits cell division by inhibiting tubulin polymerization. It disrupts the microtubule network in proliferating cells. MMAF is a auristatin derivative with a charged Cterminal phenylalanine that attenuates its cytotoxic activity compared with the uncharged counterpart monomethyl auristatin E, 11, 25, 29, 30 because the carboxylic acid terminus of free MMAF potentially limits passive transit through cell membranes. 25 ,31 MMAF induces potent antitumor effects when conjugated via a protease cleavable linker to an mAb that targets tumor-specific cell surface antigens. Although the linker to the mAb is stable in the extracellular fluid, the conjugate is cleaved by cathepsin B once it is internalized into the tumor cells and the antimitotic mechanism is activated. 30 The efficacy of an ADC depends on several factors, such as expression levels of the target antigen on tumor cells, the binding affinity of the ADC for the antigen, efficacy of internalization into the cells, and the cytotoxicity of the drug within the cells. Our in vitro ADC assay showed that HeLa and ME180 cancer cells highly expressing GPC1 were highly sensitive to GPC1-ADC, while RMG-1 cells with low expression of GPC1 were insensitive to GPC1-ADC. This suggests that certain expression levels of GPC1 seem to be required for GPC1-ADC to effectively inhibit cancer cells. Considering that MMAF interferes with microtubule dynamics in dividing cells, our ADC that incorporates a microtubule inhibitor as the drug would be expected to have only moderate toxicity, since normal cells have lower GPC1 expression levels and lower rates of cell division than do cancer cells. 32 By using GPC1-ADC, a significant antitumor effect was observed in both ME180-and HeLa-xenografted mice (Figs.  4a and 4b ). In addition, G2/M phase cell cycle arrest was specifically induced in tumor cells by the MMAF delivered by the GPC1-ADC (Fig. 4) . Compared with ME180 xenografted mice, the antitumor effect of the GPC1-ADC was less marked in HeLa-xenografted mice. IHC analysis of xenografted tumor tissues indicated that GPC1 expression levels were homogeneous in tumor cells in both cell lines (Figs. 4a  and 4b) . The difference of sensitivity to GPC1-ADC of these two xenograft models might therefore be attributed to differences in the tumor growth rate, as HeLa-induced tumors grew much more rapidly than did ME180-induced tumors in vivo (Fig. 4) . We thus demonstrated a significant antitumor effect in mouse models by conjugating an anti-GPC1 mAb (01a033) with MMAF. While these results are encouraging, more work must be done to assess whether this ADC is effective and safe for eventual clinical application.
Importantly, we confirmed that GPC1 expression in uterine cervical cancer was detected not only in primary tumors but also in one that had relapsed after chemoradiation therapy. Such relapse carries a very grim prognosis. 33 To treat recurrent cervical cancer in a previously irradiated field requires an extended surgical operation with a high rate of complications. Therefore, new therapeutic options are needed for such patients, and our study suggests that GPC1-ADC might be one such promising treatment for patients with recurrent cervical cancer. For clinical application of GPC1-ADC, humanization of the anti-GPC1 mAb is required. However, our data warrant further investigation of GPC1-ADC as a new therapeutic modality for patients with advanced and/or relapsed uterine cervical cancer, as well as other GPC1-positive tumors.
